Puma Biotechnology (PBYI) EPS (Weighted Average and Diluted) (2019 - 2026)
Puma Biotechnology (PBYI) reported EPS (Weighted Average and Diluted) of -$0.07 for Q1 2026, down 216.67% on a YoY basis from $0.06 in Q1 2025, and down 126.92% quarter-over-quarter from $0.26 in Q4 2025.
Puma Biotechnology (PBYI) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Puma Biotechnology has reported EPS (Weighted Average and Diluted) for 8 years, with the latest figure at -$0.07 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 216.67% year-over-year to -$0.07; the trailing twelve-month figure through Mar 2026 stood at $0.48 (down 38.46% YoY), and the FY2025 full-year result was $0.61, down 1.61% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.07, down from $0.26 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.41 in Q3 2024, with the low at -$0.13 in Q4 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged $0.09 across 5 years, with a median of $0.06 in 2025.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) jumped 1300.0% — and 2024, when it slumped 433.33%.
- Puma Biotechnology's EPS (Weighted Average and Diluted) stood at -$0.13 in 2022, then jumped by 292.31% to $0.25 in 2023, then surged by 60.0% to $0.4 in 2024, then plunged by 35.0% to $0.26 in 2025, then sank by 126.92% to -$0.07 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.07 (Q1 2026), $0.26 (Q4 2025), and $0.17 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Puma Biotechnology | 384.39 Mn | 282.84 Mn | 34.39 Mn | -0.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.07 |
| Dec 31, 2025 | 0.26 |
| Sep 30, 2025 | 0.17 |
| Jun 30, 2025 | 0.12 |
| Mar 31, 2025 | 0.06 |
| Dec 31, 2024 | 0.40 |
| Sep 30, 2024 | 0.41 |
| Jun 30, 2024 | -0.09 |
| Mar 31, 2024 | -0.10 |
| Dec 31, 2023 | 0.25 |
| Sep 30, 2023 | 0.12 |
| Jun 30, 2023 | 0.05 |
| Mar 31, 2023 | 0.03 |
| Dec 31, 2022 | -0.13 |
| Sep 30, 2022 | -0.01 |
| Jun 30, 2022 | 0.21 |
| Mar 31, 2022 | -0.08 |
| Dec 31, 2021 | 0.10 |
| Sep 30, 2021 | -1.09 |
| Jun 30, 2021 | -0.13 |